NCT06381076CompletedPhase 3
High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis.
Examining the Impact of High-protein Oral Supplement With Liposomal Curcumin on Inflammation Markers and Oxidative Stress in Adults Undergoing Hemodialysis.
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
A 12-week double-blind randomized control trial will be conducted among adults on hemodialysis (n=15) to determine the impact of liposomal curcumin in a high-protein product on inflammation markers and oxidative stress. Participants will be randomized via a computer-generator into either the control or intervention group. Participants in each group will be given a total of 38 g of a high protein product with or without 7 mls of liposomal curcumin for a total of 8 weeks. At baseline, weeks 8 and 12, participants will have blood sampled and complete a 3-day 24-hour recalls (2 non-dialysis days and 1 dialysis day) and a quality of life survey.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- First submitted
- 19 Apr 2024
- Start date
- 3 Feb 2025
- Primary completion date
- 13 May 2025
- Lead sponsor
- University of Florida
- Diseases
- Chronic kidney disease
- NCT number
- NCT06381076
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 39
- From 3 Feb 2025 to the primary completion date, 13 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Adults with CKD stages 1-4.
- Adults undergoing peritoneal dialysis.
- Pregnant and/or lactating for the duration of the study as confirmed by the dialysis medical staff.
- Use of other IP within 3 months of the initiation of the study.
Who the study is looking for
- 18 years old or older
- diagnosed with stage 5 CKD.
- receiving hemodialysis at least three months before the trial start date
- All participants can provide signed informed consent, have no dietary restrictions, no food allergies, nor chewing/swallowing difficulties.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Florida Coordinator of this site? Confirm its status | Gainesville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.